MTI-201​

MTI-201 is an intravenously administered precision targeted alpha radio therapy for treating metastatic melanoma, which otherwise will not respond to current standard of care therapies. This novel compound selectively targets the highly expressed MC1R receptor found on metastatic melanoma and carries a payload of the Actinium 225 alpha particle to the target, effectively killing advanced stage treatment resistant melanoma cancers without significant damage to healthy tissues due to highly specific targeting and very short radiation distance from the alpha particle.